Lifecare scientific updates: CGM symposium in Bergen, consensus recommendations from the Diabetes Technology Society and presentation of data at ATTD 2025

20 Mar 2025 07:00 CET

Bergen, Norway, 20 March 2025 -- Lifecare ASA (LIFE) is a medical sensor
company advancing product development for the next-generation Continuous
Glucose Monitoring (CGM). This week, Lifecare successfully hosted a
high-profile symposium, contributed to a global consensus recommendation
alongside Novo Nordisk, and is set to present data at the Advanced
Technologies & Treatment for Diabetes (ATTD) conference in Amsterdam.

Lifecare CGM symposium at Eitri, Haukeland University Hospital

17 March 2025 Lifecare brought together world-renowned experts for the
Lifecare CGM-Symposium 2025 at Eitri, Haukeland University Hospital in Bergen,
Norway. Professor David Klonoff (Diabetes Research Institute, Mills-Peninsula
Medical Center, San Mateo and UCSF, CA, USA), Niels Ejskjær (Aalborg
University Hospital), Simon Dankel (University of Bergen), and Andreas
Pfützner (Lifecare and DTMD University, Luxembourg) shared insights on the
evolution of Continuous Glucose Monitoring, discussing past, present, and
future perspectives. The symposium explored state-of-the-art CGM technologies,
including Lifecare's proprietary osmotic-pressure-based sensor, a novel
approach aiming to revolutionize glucose monitoring with increased accuracy
and longevity.

Among the key topics covered at the symposium were:

* Next-generation CGM devices -- including nano-printed,
osmotic-pressure-based sensors from Lifecare.
* Glucose-dependent insulin -- an emerging technology with the potential to
deliver insulin that only activates at high glucose levels.
* AI-powered Glycemic Risk Index (GRI) -- a software tool that synthesizes
large amounts of CGM data to aid physicians in making faster, data-driven
decisions.
* In-hospital diabetes management -- addressing the inadequacies in current
clinical protocols.

"Technology is key to transforming diabetes care", says Joacim Holter, CEO of
Lifecare. "This symposium was an excellent platform to discuss the latest
advancements and Lifecare's role in the future of CGM innovation."

In addition to the scientific program, Marta Helgidottir, a representative
from the Norwegian Diabetes Association, shared her personal story of being a
mother to a four -year-old girl with Type 1 diabetes.

- The patient perspective is fundamentally important for the work at Lifecare
and such testimonies are highly valued. The Lifecare team looks forward to the
next CGM symposium, says CEO Joacim Holter.

Lifecare supports the Diabetes Technology Society global consensus on GLP-1
and Type 1 Diabetes.

Lifecare has contributed as a sponsor, alongside Novo Nordisk, for a Consensus
Recommendations on the use of GLP-1 Receptor Agonists in Type 1 Diabetes,
hosted by the Diabetes Technology Society and chaired by Professor David
Klonoff (Diabetes Research Institute, Mills-Peninsula Medical Center, San
Mateo and UCSF, CA, USA) and Professor Viral N. Shah (Indiana University
School of Medicine, IN, USA).

This significant global initiative, spearheaded by 19 leading global diabetes
technology experts, aims to establish clinical guidelines for integrating
GLP-1 receptor agonists into type 1 diabetes management, offering new
therapeutic avenues for improved glycemic control and patient outcomes.

- We are happy to sponsor this publication from The Diabetes Technology
Society. These recommendations aim to guide clinicians and researchers in
optimizing the use of GLP-1RAs alongside AID systems to improve outcomes for
individuals with T1D, says CEO Joacim Holter.

For further details, visit: Diabetes Technology Society
(https://www.diabetestechnology.org/glp1t1d/).

Lifecare presents data at ATTD 2025

This week, Lifecare will showcase scientific findings at ATTD in Amsterdam,
highlighting the latest results from its Sencell CGM development program. The
Poster presentation will focus on human and veterinary studies evaluating
Lifecare's proprietary osmotic-pressure-based glucose sensor, which aims to
set a new benchmark for accuracy and longevity in CGM technology.

Study results indicate that Lifecare's Sencell sensor demonstrates a Mean
Absolute Relative Difference (MARD) of 9.6%, placing it in line with leading
commercial CGM devices. The sensor, which is designed to function for a
minimum of 6 months has successfully tracked glucose concentrations comparable
to existing needle-based CGMs, paving the way for further development in
wireless data and energy transfer.

"Our ongoing product development continues to validate the Sencell sensor's
unique capabilities," said Joacim Holter. "We are committed to delivering a
next-generation CGM solution that enhances both patient experience and
clinical outcomes."

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

More information:
Access the news on Oslo Bors NewsWeb site

641710_Lifecare scientific updates- CGM symposium in Bergen, consensus recommendations from the Diabetes Technology Society and presentation of data at ATTD 2025.pdf